Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 348 B
EBIT 2017 -
Net income 2017 22 430 M
Finance 2017 22 194 M
Yield 2017 1,24%
Sales 2018 354 B
EBIT 2018 -
Net income 2018 23 610 M
Finance 2018 34 220 M
Yield 2018 1,30%
P/E ratio 2017 47,43
P/E ratio 2018 44,38
EV / Sales2017 3,28x
EV / Sales2018 3,19x
Capitalization 1 164 B
More Financials
Company
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products.It operates through the Pharmaceuticals and Bio-Chemicals segments.The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Kyowa Hakko Kirin Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on KYOWA HAKKO KIRIN CO LTD
10/19 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline for Parkinson's ..
10/17 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline (KW-6002) for Pa..
10/12 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
10/12 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
10/11 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
10/10 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and..
10/10 Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197
10/09 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
10/06 KYOWA HAKKO KIRIN : Announces Discontinuation for Developing ARQ 197 (Tivantinib..
10/05 SYNDAX PHARMACEUTICALS, INC. (NASDAQ : SNDX) Files An 8-K Other Events
More news
Sector news : Specialty & Advanced Pharmaceuticals
06:45p MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
11:45aDJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
10/10Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review .. 
10/10BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S.. 
09/29Kyowa Hakko Kirin : Notice Concerning Share Transfer Associated with Change i.. 
09/14Kyowa Hakko Kirin : Acquired Approval for Additional formulation of ACOALAN® .. 
09/12Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Link.. 
More tweets
Qtime:13
News from SeekingAlpha
04/10 3 THINGS IN BIOTECH YOU SHOULD LEARN : Volume 4
01/05 Ultragenyx and Kyowa Kirin announce MAA for KRN23 filed and accepted for revi..
2016 ArQule Is Undervalued Going Into Catalyst Events
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 247  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Masashi Miyamoto Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD24.78%10 167
ABBVIE53.37%153 097
MERCK KGAA-4.68%14 409
JAZZ PHARMACEUTICALS PLC28.83%8 437
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 792
CONVATEC GROUP-9.02%5 572